Fluvastatin treatment was associated with a moderate beneficial effect on SARS-CoV-2 infection, suggesting it may improve clinical outcomes for patients with COVID-19.
Children treated with long-term low-dose ICS showed significantly improved asthma control test (C-ACT) scores compared to those treated for shorter durations, indicating better asthma management.
JZOL showed comparable efficacy to western medicine in reducing cough and improving expectoration, with a median time-to-cough resolution of 5 days.
The study found that asthma accounted for 36% of diagnoses, highlighting the importance of thorough investigation in children with prolonged or recurrent cough, leading to appropriate treatment and improved quality of life.
Increased apoptosis limited airway contractile tissue growth, suggesting a potential therapeutic pathway for asthma management.
The study aims to demonstrate improvements in asthma control, quality of life, and pulmonary function in patients receiving IFT alongside bronchodilator therapy, particularly when applied in specific body positions.
Expected positive outcomes include improved pulmonary function parameters such as Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1), and the FEV1/FVC ratio, along with enhanced exercise tolerance and quality of life for COPD patients.
Improved recognition and management of chronic respiratory symptoms and COPD in post-PTB patients, leading to better morbidity and quality of life outcomes, especially in those with immunosuppressive conditions.